Chesnara plc (CSN): Showing good operational progress
Chesnara announced its 2024 results, which showed positive progress compared with 2023. The main features were positive market returns, offset by...
211 Views
Hardman & Co Insight: 2024 Pharma Statistics
This report provides the first snapshot of global pharmaceutical market growth plus the global and US company rankings for 2024.
162 Views
Apax Global Alpha (APAX): Jam yesterday, and tomorrow, but not today
AGA was transparent in that 2024 was a below-average year for the company, with a total NAV return of 0.8% (-3.0% constant currency, including a...
180 Views
H&T (HAT) - 2024 results: reasons to be cheerful 1, 2, 3, 4 and 5
H&T’s 2024 results were reassuringly in line with expectations, delivering 10% PBT growth, with the pledge book capital value up 26%, retail...
181 Views
NB Private Equity Partners (NBPE): Update on: NAV, capital, Trump and interest rates
We highlighted our capital markets day takeaways in CM day: 6 November fireworks; notably, i) positive market trends, ii) NB’s platform unique...
211 Views